鹭燕医药：公司自主研发的心电、胎心等领域的产品已取得医疗器械注册认证，并启动销售，但相关收入占比较小

Group 1 - The company is focusing on innovation and is nurturing new technologies and models with potential in the AI application field [2] - The company has developed products in the fields of electrocardiograms and fetal heart monitoring, which have received medical device registration certification and have begun sales [2] - The sales revenue from these products is relatively small and has a minor impact on the company's overall performance [2] Group 2 - The company acknowledges that there are risks and challenges in the market expansion of these products, advising investors to be cautious and invest rationally [2]